This grant is for supporting innovative research to improve our understanding of immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes. This dysregulation significantly increases the risk of latent tuberculosis (TB) re-activation and leads to more severe active TB disease, often resulting in more frequent treatment failure, relapse, and death, particularly in individuals co-infected with HIV. The funding aims to advance knowledge of these complex immunological interactions, ultimately contributing to the development of more effective therapeutic strategies for these critical, converging epidemics. Applications focusing on the intricate pathways affected by DM in the context of TB and HIV co-infection are encouraged.
Opportunity ID: 293785
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PA-17-282 |
| Funding Opportunity Title: | Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy and Infectious Diseases Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 12, 2017 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Sep 07, 2020 |
| Current Closing Date for Applications: | Sep 07, 2020 |
| Archive Date: | Oct 13, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $200,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities For profit organizations other than small businesses County governments Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this funding opportunity announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PA-17-282.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-D | Use for due dates on or before January 24, 2018 | PKG00232464 | Aug 07, 2017 | Jan 24, 2018 | View | |
| FORMS-E | Use for due dates on or before May 24, 2020 | PKG00236296 | Nov 16, 2017 | May 24, 2020 | View | |
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00260051 | Aug 07, 2017 | Sep 07, 2020 | View |
Package 1
Mandatory forms
293785 RR_SF424_2_0-2.0.pdf
293785 PHS398_CoverPageSupplement_3_0-3.0.pdf
293785 RR_OtherProjectInfo_1_3-1.3.pdf
293785 PerformanceSite_2_0-2.0.pdf
293785 RR_KeyPersonExpanded_2_0-2.0.pdf
293785 PHS398_ResearchPlan_3_0-3.0.pdf
Optional forms
293785 RR_Budget_1_3-1.3.pdf
293785 RR_SubawardBudget30_1_3-1.3.pdf
293785 PHS398_ModularBudget_1_2-1.2.pdf
293785 PHS_Inclusion_Enrollment_Report-1.0.pdf
293785 PHS_AssignmentRequestForm-1.0.pdf
Package 2
Mandatory forms
293785 RR_SF424_2_0-2.0.pdf
293785 PHS398_CoverPageSupplement_4_0-4.0.pdf
293785 RR_OtherProjectInfo_1_4-1.4.pdf
293785 PerformanceSite_2_0-2.0.pdf
293785 RR_KeyPersonExpanded_2_0-2.0.pdf
293785 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
293785 RR_Budget_1_4-1.4.pdf
293785 RR_SubawardBudget30_1_4-1.4.pdf
293785 PHS398_ModularBudget_1_2-1.2.pdf
293785 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 3
Mandatory forms
293785 RR_SF424_2_0-2.0.pdf
293785 PHS398_CoverPageSupplement_5_0-5.0.pdf
293785 RR_OtherProjectInfo_1_4-1.4.pdf
293785 PerformanceSite_2_0-2.0.pdf
293785 RR_KeyPersonExpanded_2_0-2.0.pdf
293785 PHS398_ResearchPlan_4_0-4.0.pdf
293785 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
293785 RR_Budget_1_4-1.4.pdf
293785 RR_SubawardBudget30_1_4-1.4.pdf
293785 PHS398_ModularBudget_1_2-1.2.pdf
293785 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
